Events

World CDx - Boston 2015

Murali Prahalad, Ph.D., president and CEO, will give a presentation entitled "Matching the Spectrum of Cellular Heterogeneity to the Spectrum of Therapeutic Response in Cancer" at World Cdx Boston 2015

ASCO GU 2015

Epic’s collaborators are presenting three studies at the 2015 ASCO Genitourinary Cancers Symposium held in Orlando, Fla., that demonstrate how the Epic Sciences no cell left behind™ platform could be used as a blood test for certain types of metastatic prostate and bladder cancers — liquid biopsies to predict which patients will best respond to certain therapies before they are treated.

Personalized Medicine World Conference 2015

Murali Prahalad, Ph.D., president and CEO, will give a presentation entitled, “CTCs Come of Age as Biomarkers” at the Personalized Medicine World Conference (PMWC) 2015

26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Data presented on 1) PD-L1 assay on circulating tumor cells identified in a liquid biopsy from non-small cell lung cancer patients and 2) a new assay for NSCLC Biomarkers, including EGFR, KRAS, ALK, MET, RET and ROS1, utilizing both circulating tumor cells (CTC) and circulating free DNA (cfDNA) from a single tube of blood

ESMO 2014

Poster Display Session 28.09.2014 | 12:45 - 13:45 Characteristics of de novo resistance to androgen targeting therapeutics (AR Tx) through circulating tumor cells (CTCs) analysis in metastatic castration resistant prostate cancer (mCRPC) patients R. Bambury, J. Louw, R. Krupa, D. Danila, Z. Arslan, N. Schreiber, A. Jendrisak, D. Marrinucci, R. Dittamore, H. Scher

AACR14: Data from Epic’s CTC Technology in Prostate and Lung Cancer

In collaboration with the company's academic and pharmaceutical partners, Epic's technology will be featured in two talks and two posters at the 105th Annual Meeting of the American Association for Cancer Research (AACR), April 5-9, 2014 in San Diego.

ASCO GU 2014: Epic and Collaborators Presents Six Abstracts

Studies address technical sensitivity, specificity, pharmacodynamics, heterogeneity, and patient selection relevant to prostate cancer patient management

Epic Sciences’ Research in Prostate Cancer Presented at the 2013 ASCO Genitourinary Cancers Symposium

SAN DIEGO and ORLANDO, FLA. - February 12, 2013 -- Epic Sciences, Inc. ("Epic"), a private biotech company that develops breakthrough cancer diagnostics, announced the presentation of a research poster at the 2013 Genitourinary Cancers Symposium taking place February 14 to 16 in Orlando, Fla. The symposium presents the latest research in genitourinary cancers and is sponsored by three leading medical specialty societies: American Society of Clinical Oncology (ASCO), the American Society for Radiation Oncology (ASTRO) and the Society of Urologic Oncology (SUO).

2H2012 Conferences

Epic Sciences will be at the following 2012 conferences and events:

1H2012 Conferences

Epic Sciences will be at the following 2012 conferences and events: